search
Back to results

Indocyanine Green Versus Blue Dye for Detection of Sentinel Lymph Node In Endometrial Cancer

Primary Purpose

Endometrial Neoplasms

Status
Completed
Phase
Phase 3
Locations
Canada
Study Type
Interventional
Intervention
Sentinel lymph node biopsy
Sponsored by
Centre hospitalier de l'Université de Montréal (CHUM)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Endometrial Neoplasms focused on measuring Indocyanine Green, Sentinel Lymph Node Biopsy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • all patients with endometrial carcinoma proven by endometrial biopsy or curettage AND
  • preoperative FIGO (International Federation of Gynecology and Obstetrics) stage I AND
  • intended for staging via laparoscopic or robotic surgery AND
  • Patients must be older than 18 year-old, able to read French or English.

Exclusion Criteria:

  • preoperative FIGO stages II to IV
  • previous pelvic or paraaortic lymphadenectomy or radiotherapy
  • surgery that could change the uterine lymphatic drainage (myomectomy)
  • iodine allergy
  • pregnancy.

Sites / Locations

  • Centre Hospitalier Universitaire Montréal Hôpital Saint Luc

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Indocyanine Green on the right side

Methylene Blue on the right side

Arm Description

Indocyanine Green will be injected on the right side of the cervix and Methylene blue on the left side of the cervix.

Methylene blue will be injected on the right side of the cervix and Indocyanine Green on the left side of the cervix.

Outcomes

Primary Outcome Measures

the difference in the proportion of hemipelves with successful detection of SLN according to the dye used

Secondary Outcome Measures

Full Information

First Posted
September 29, 2015
Last Updated
January 23, 2018
Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
search

1. Study Identification

Unique Protocol Identification Number
NCT02564276
Brief Title
Indocyanine Green Versus Blue Dye for Detection of Sentinel Lymph Node In Endometrial Cancer
Official Title
Indocyanine Green Versus Blue Dye for Detection of Sentinel Lymph Node In Endometrial Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
June 2016
Overall Recruitment Status
Completed
Study Start Date
February 2016 (undefined)
Primary Completion Date
April 2017 (Actual)
Study Completion Date
July 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To determine the difference in the proportion of hemipelves with successful detection of Sentinel Lymph Node according to the dye used (indocyanine green with near-infrared imaging vs blue dye) in women with endometrial cancer.
Detailed Description
In the past few years, Sentinel Lymph Node (SLN) procedure has emerged as an interesting solution to the debate on lymphadenectomy in endometrial cancer. Using blue-dye is inexpensive but results in an unsatisfactory detection rate of SLN. IndoCyanine Green (ICG) with near-infrared imaging is a novel technology for SLN mapping and initial reports on the use of ICG have shown high detection rate. In the present study, we aim to determine precisely the increase in detection rate of SLN associated with the use of ICG instead of blue dye. This randomized controlled trial will include patients with preoperative stage I endometrial carcinoma. All included women will undergo SLN mapping with blue dye in one hemipelvis and ICG in the other hemipelvis. Randomization will concern the side of the hemipelvis in which blue dye vs ICG mapping is used, so that the patient's contralateral hemipelvis will serve as a control to her ipsilateral hemipelvis. The primary endpoint is the difference in the proportion of hemipelves with successful detection of SLN according to the dye used. The unique precise information gained from the present study will contribute to determine whether the benefit of the use of ICG over blue dye is sufficient to justify the expense of its use.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Endometrial Neoplasms
Keywords
Indocyanine Green, Sentinel Lymph Node Biopsy

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
132 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Indocyanine Green on the right side
Arm Type
Experimental
Arm Description
Indocyanine Green will be injected on the right side of the cervix and Methylene blue on the left side of the cervix.
Arm Title
Methylene Blue on the right side
Arm Type
Experimental
Arm Description
Methylene blue will be injected on the right side of the cervix and Indocyanine Green on the left side of the cervix.
Intervention Type
Procedure
Intervention Name(s)
Sentinel lymph node biopsy
Primary Outcome Measure Information:
Title
the difference in the proportion of hemipelves with successful detection of SLN according to the dye used
Time Frame
at time of surgery

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: all patients with endometrial carcinoma proven by endometrial biopsy or curettage AND preoperative FIGO (International Federation of Gynecology and Obstetrics) stage I AND intended for staging via laparoscopic or robotic surgery AND Patients must be older than 18 year-old, able to read French or English. Exclusion Criteria: preoperative FIGO stages II to IV previous pelvic or paraaortic lymphadenectomy or radiotherapy surgery that could change the uterine lymphatic drainage (myomectomy) iodine allergy pregnancy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Béatrice Cormier, MD
Organizational Affiliation
Centre hospitalier de l'Université de Montréal (CHUM)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre Hospitalier Universitaire Montréal Hôpital Saint Luc
City
Montréal
State/Province
Quebec
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
3652025
Citation
Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987 Oct 15;60(8 Suppl):2035-41. doi: 10.1002/1097-0142(19901015)60:8+3.0.co;2-8.
Results Reference
result
PubMed Identifier
16740298
Citation
Abu-Rustum NR, Alektiar K, Iasonos A, Lev G, Sonoda Y, Aghajanian C, Chi DS, Barakat RR. The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecol Oncol. 2006 Nov;103(2):714-8. doi: 10.1016/j.ygyno.2006.03.055. Epub 2006 Jun 5.
Results Reference
result
PubMed Identifier
3663535
Citation
Dankert J, Bouma J. Recurrent acute leg cellulitis after hysterectomy with pelvic lymphadenectomy. Br J Obstet Gynaecol. 1987 Aug;94(8):788-90. doi: 10.1111/j.1471-0528.1987.tb03728.x.
Results Reference
result
PubMed Identifier
16677594
Citation
Querleu D, Leblanc E, Cartron G, Narducci F, Ferron G, Martel P. Audit of preoperative and early complications of laparoscopic lymph node dissection in 1000 gynecologic cancer patients. Am J Obstet Gynecol. 2006 Nov;195(5):1287-92. doi: 10.1016/j.ajog.2006.03.043. Epub 2006 May 3.
Results Reference
result
PubMed Identifier
22366409
Citation
Barlin JN, Khoury-Collado F, Kim CH, Leitao MM Jr, Chi DS, Sonoda Y, Alektiar K, DeLair DF, Barakat RR, Abu-Rustum NR. The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecol Oncol. 2012 Jun;125(3):531-5. doi: 10.1016/j.ygyno.2012.02.021. Epub 2012 Feb 22.
Results Reference
result
PubMed Identifier
25175452
Citation
Desai PH, Hughes P, Tobias DH, Tchabo N, Heller PB, Dise C, Slomovitz BM. Accuracy of robotic sentinel lymph node detection (RSLND) for patients with endometrial cancer (EC). Gynecol Oncol. 2014 Nov;135(2):196-200. doi: 10.1016/j.ygyno.2014.08.032. Epub 2014 Aug 28.
Results Reference
result
PubMed Identifier
26047592
Citation
Cormier B, Rozenholc AT, Gotlieb W, Plante M, Giede C; Communities of Practice (CoP) Group of Society of Gynecologic Oncology of Canada (GOC). Sentinel lymph node procedure in endometrial cancer: A systematic review and proposal for standardization of future research. Gynecol Oncol. 2015 Aug;138(2):478-85. doi: 10.1016/j.ygyno.2015.05.039. Epub 2015 Jun 3.
Results Reference
result
PubMed Identifier
21489874
Citation
Ballester M, Dubernard G, Lecuru F, Heitz D, Mathevet P, Marret H, Querleu D, Golfier F, Leblanc E, Rouzier R, Darai E. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol. 2011 May;12(5):469-76. doi: 10.1016/S1470-2045(11)70070-5. Epub 2011 Apr 12.
Results Reference
result

Learn more about this trial

Indocyanine Green Versus Blue Dye for Detection of Sentinel Lymph Node In Endometrial Cancer

We'll reach out to this number within 24 hrs